

LISTING OF CLAIMS:

Claim 1 (Currently amended) An immunogenic composition comprising an antibody inducing effective amount of a construct comprising a proteosome-gp 160 complex and a pharmaceutically acceptable carrier, wherein 1) the complex induces the formation of an antibody that binds gp 160 which antibody formation is further enhanced by at least 1.5 fold with an adjuvant, and 2) the proteosome and the gp 160 are present in a ratio which ranges from 1:1 to 1:3, and 3) the complex is formed by a) lyophilizing a mixture of gp 160 and proteosomes, b) dialysis of a mixture of gp 160 and proteosomes or c) by mixing gp 160 with proteosomes, and a pharmaceutically acceptable carrier.

Claim 2 (Previously cancelled).

Claim 3 (Previously presented): A composition of claim 1 further comprising an adjuvant.

Claim 4 (Original): A composition of claim 3 wherein the adjuvant is alum.

Claim 5 (Previously cancelled).

Claim 6 (Previously cancelled).

Claim 7 (Previously amended): The composition according to claim 1 wherein the ratio is 1:1.

Claim 8 (Previously amended) A method for inducing antibody formation in a host comprising administering an effective amount of the composition of claim 1 to host to induce the formation of an antibody that specifically binds gp160.

Claim 9 (Cancel).

Claim 10 (Previously amended): The composition of claim 1 wherein the complex is formed by lyophilizing a mixture of gp160 and proteosomes.

Claim 11 (Previously amended): The composition of claim 1 wherein the complex is formed by the dialysis of a mixture of gp160 and proteosomes.

Claim 12 (Previously presented): The composition of claim 1 wherein the complex is formed by mixing gp 160 with proteosomes.

Claim 13 (Previously presented): The composition of claim 1 further comprising submicron emulsion (SEM).